应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02142 和铂医药-B
休市中 05-02 16:08:25
8.810
+0.210
+2.44%
最高
8.840
最低
8.520
成交量
339.20万
今开
8.600
昨收
8.600
日振幅
3.72%
总市值
73.56亿
流通市值
73.56亿
总股本
8.35亿
成交额
2,971万
换手率
0.41%
流通股本
8.35亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
和铂医药-B(02142)4月30日斥资231.56万港元回购27万股
智通财经 · 04-30 10:53
和铂医药-B(02142)4月30日斥资231.56万港元回购27万股
和铂医药-B04月30日遭主力抛售62.8万元
市场透视 · 04-30 08:15
和铂医药-B04月30日遭主力抛售62.8万元
和铂医药-B授出487.5万份购股权
格隆汇 · 04-29
和铂医药-B授出487.5万份购股权
和铂医药-B盘中异动 大幅上涨5.04%
市场透视 · 04-25
和铂医药-B盘中异动 大幅上涨5.04%
港股异动 | 和铂医药-B(02142)再涨超4% 公司与阿斯利康合作深化 已与多家MNC达成合作协议
智通财经 · 04-25
港股异动 | 和铂医药-B(02142)再涨超4% 公司与阿斯利康合作深化 已与多家MNC达成合作协议
和铂医药再涨超4%公司与阿斯利康合作深化已与多家MNC达成合作协议
动脉网 · 04-25
和铂医药再涨超4%公司与阿斯利康合作深化已与多家MNC达成合作协议
和铂医药-B盘中异动 股价大涨5.10%
市场透视 · 04-24
和铂医药-B盘中异动 股价大涨5.10%
和铂医药-B4月23日斥资315.9万港元回购40万股
新浪港股 · 04-24
和铂医药-B4月23日斥资315.9万港元回购40万股
和铂医药-B(02142)4月23日斥资315.9万港元回购40万股
智通财经 · 04-23
和铂医药-B(02142)4月23日斥资315.9万港元回购40万股
和铂医药高管降薪
Insight数据库 · 04-23
和铂医药高管降薪
和铂医药-B盘中异动 早盘股价大涨5.01%报7.540港元
市场透视 · 04-22
和铂医药-B盘中异动 早盘股价大涨5.01%报7.540港元
和铂医药-B(02142)4月17日斥资209.13万港元回购28.9万股
智通财经 · 04-17
和铂医药-B(02142)4月17日斥资209.13万港元回购28.9万股
和铂医药-B04月17日主力净流出519万元 散户资金买入
市场透视 · 04-17
和铂医药-B04月17日主力净流出519万元 散户资金买入
和铂医药-B(02142)4月16日斥资539万港元回购75万股
智通财经 · 04-16
和铂医药-B(02142)4月16日斥资539万港元回购75万股
和铂医药人事变动:陈侑晨任首席财务官 直接向创始人汇报
GPLP犀牛财经 · 04-16
和铂医药人事变动:陈侑晨任首席财务官 直接向创始人汇报
和铂医药-B盘中异动 急速下跌5.48%报7.240港元
市场透视 · 04-16
和铂医药-B盘中异动 急速下跌5.48%报7.240港元
港股异动 | 医药股涨幅居前 再鼎医药(09688)涨近15% 和铂医药-B(02142)涨超10%
智通财经 · 04-14
港股异动 | 医药股涨幅居前 再鼎医药(09688)涨近15% 和铂医药-B(02142)涨超10%
港股生物医药股大幅上涨,永泰生物-B涨超15%
老虎资讯综合 · 04-14
港股生物医药股大幅上涨,永泰生物-B涨超15%
和铂医药-B早盘涨近8% 2024年12月初至今累计涨幅已超580%
新浪港股 · 03-11
和铂医药-B早盘涨近8% 2024年12月初至今累计涨幅已超580%
港股异动 | 和铂医药-B(02142)再涨超7% 公司正式任命首席战略官 负责拓展全球业务
智通财经 · 03-11
港股异动 | 和铂医药-B(02142)再涨超7% 公司正式任命首席战略官 负责拓展全球业务
加载失败,点击重试
公司概况
公司名称:
和铂医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。其中,巴托利单抗(HBM9161)主要用于免疫性血小板减少症、甲状腺相关性眼病、重症肌无力、视神经脊髓炎谱系疾病等. 特那西普(HBM9036)主要用于干眼病。此外,该公司还研究和开发肿瘤免疫产品管线,包括内部开发的新一代肿瘤免疫资产,针对治疗免疫沙漠型、免疫排斥型及炎症型肿瘤。该公司拥有Harbour Mice平台,该平台能够产生经典的双重链双轻链(H2L2)形式及仅重链(HCAb)形式的全人源单克隆抗体。
发行价格:
--
{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":8.81,"timestamp":1746173305030,"preClose":8.6,"halted":0,"volume":3392000,"delay":0,"floatShares":835000000,"shares":835000000,"eps":0.028024056048112096,"marketStatus":"休市中","change":0.21,"latestTime":"05-02 16:08:25","open":8.6,"high":8.84,"low":8.52,"amount":29710113,"amplitude":0.037209,"askPrice":8.81,"askSize":48000,"bidPrice":8.79,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":0.028024056048112096,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":8.6,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.430526775147529,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142/tweets","defaultTab":"tweets","newsList":[{"id":"2531080318","title":"和铂医药-B(02142)4月30日斥资231.56万港元回购27万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531080318","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531080318?lang=zh_cn&edition=full","pubTime":"2025-04-30 18:53","pubTimestamp":1746010387,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和铂医药-B(02142)发布公告,该公司于2025年4月30日斥资231.56万港元回购27万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)4月30日斥资231.56万港元回购27万股","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2531085105","title":"和铂医药-B04月30日遭主力抛售62.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531085105?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000932,"startTime":"0","endTime":"0","summary":"04月30日,和铂医药-B股价收平报8.60元,成交金额5513.6万元,换手率0.76%,振幅3.84%,量比0.72。和铂医药-B今日主力资金净流出62.8万元,连续3日净流出,上一交易日主力净流出92.8万元。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为60.00%,平均跌幅为5.68%。该股近5个交易日上涨9.94%,主力资金累计净流出828.8万元;近20日主力资金累计净流出1852.4万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170725a46d7445&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170725a46d7445&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2531476759","title":"和铂医药-B授出487.5万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2531476759","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531476759?lang=zh_cn&edition=full","pubTime":"2025-04-29 22:31","pubTimestamp":1745937101,"startTime":"0","endTime":"0","summary":"格隆汇4月29日丨和铂医药-B(02142.HK)公告,于2025年4月29日,根据公司股东于2020年11月23日采纳的购股权计划,公司向合资格参与者授出购股权487.5万份,惟须待承授人接纳后生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429223141974a4bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429223141974a4bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2530597392","title":"和铂医药-B盘中异动 大幅上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530597392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530597392?lang=zh_cn&edition=full","pubTime":"2025-04-25 15:00","pubTimestamp":1745564444,"startTime":"0","endTime":"0","summary":"2025年04月25日下午盘15时00分,和铂医药-B股票出现波动,股价急速上涨5.04%。截至发稿,该股报8.340港元/股,成交量816.3万股,换手率0.98%,振幅5.16%。和铂医药-B股票所在的生物技术行业中,整体跌幅为1.51%。其相关个股中,腾盛博药-B、和铂医药-B、荃信生物-B涨幅较大,振幅较大的相关个股有创胜集团-B、歌礼制药-B、来凯医药-B,振幅分别为15.62%、12.18%、11.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251500449744a0a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251500449744a0a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2530924793","title":"港股异动 | 和铂医药-B(02142)再涨超4% 公司与阿斯利康合作深化 已与多家MNC达成合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2530924793","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530924793?lang=zh_cn&edition=full","pubTime":"2025-04-25 14:27","pubTimestamp":1745562446,"startTime":"0","endTime":"0","summary":"消息面上,和铂医药3月发布公告称,与阿斯利康订立全球战略合作协议,共同研发针对免疫性疾病、肿瘤及其他多种疾病的新一代多特异性抗体。太平洋证券指出,和铂医药已多次获得阿斯利康的青睐。和铂医药凭借3次合作,以及此次超45亿美元的潜在总交易金额,稳居阿斯利康中国BD交易榜首。除了阿斯利康之外,和铂医药还曾与辉瑞、艾伯维等多家MNC达成合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU0320765992.SGD","BK4007","02142","LU0109394709.USD","LU2236285917.USD","BK1161","LU1829250122.USD","LU2417539215.USD","BK4588","LU0889565916.HKD","BK1583","AZN","BK4568","LU2456880835.USD","LU2462157665.USD","BK1574"],"gpt_icon":0},{"id":"2530927861","title":"和铂医药再涨超4%公司与阿斯利康合作深化已与多家MNC达成合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2530927861","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530927861?lang=zh_cn&edition=full","pubTime":"2025-04-25 14:27","pubTimestamp":1745562420,"startTime":"0","endTime":"0","summary":"和铂医药与阿斯利康深化合作,共建创新中心,并获得多家跨国药企青睐,凭借其专有技术平台不断发展。股价再涨超4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042514344894e20e10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042514344894e20e10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU2417539215.USD","BK4568","LU2456880835.USD","LU1829250122.USD","BK4585","AZN","BK4007","LU2236285917.USD","LU0320765992.SGD","LU2462157665.USD","BK4588","LU0889565916.HKD","02142"],"gpt_icon":0},{"id":"2529710613","title":"和铂医药-B盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529710613","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529710613?lang=zh_cn&edition=full","pubTime":"2025-04-24 09:51","pubTimestamp":1745459499,"startTime":"0","endTime":"0","summary":"2025年04月24日早盘09时51分,和铂医药-B股票出现异动,股价快速上涨5.10%。截至发稿,该股报8.250港元/股,成交量88.3001万股,换手率0.11%,振幅4.59%。机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。和铂医药-B股票所在的生物技术行业中,整体涨幅为1.06%。其相关个股中,荣昌生物、宜明昂科-B、亚盛医药-B涨幅较大,振幅较大的相关个股有北海康成-B、博安生物、歌礼制药-B,振幅分别为12.10%、9.50%、8.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424095139aa2c796b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424095139aa2c796b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","02142","BK1161"],"gpt_icon":1},{"id":"2529691711","title":"和铂医药-B4月23日斥资315.9万港元回购40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529691711","media":"新浪港股","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529691711?lang=zh_cn&edition=full","pubTime":"2025-04-24 08:33","pubTimestamp":1745454780,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 和铂医药-B(02142)发布公告,于2025年4月23日该公司斥资315.9万港元回购40万股,回购价格为每股7.84-7.92港元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-24/doc-ineufnmf3119006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2529502585","title":"和铂医药-B(02142)4月23日斥资315.9万港元回购40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502585","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529502585?lang=zh_cn&edition=full","pubTime":"2025-04-23 20:07","pubTimestamp":1745410069,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和铂医药-B(02142)发布公告,于2025年4月23日该公司斥资315.9万港元回购40万股,回购价格为每股7.84-7.92港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2529631442","title":"和铂医药高管降薪","url":"https://stock-news.laohu8.com/highlight/detail?id=2529631442","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529631442?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:14","pubTimestamp":1745399690,"startTime":"0","endTime":"0","summary":"4 月 22 日,和铂医药发布 2024 年报告,其中披露了公司首席执行官和首席科学官的薪酬,与 2023 年相比均有所下滑。来源:和铂医药 2024 年年报创始人、董事长兼首席执行官王劲松博士2024 年薪酬为 139 万美元,与 2023 年的 158.5 万美元相比,下滑 12.3%。和铂医药 2024 年营收 3810 万美元,盈利 274.2 万美元。值得注意的是,该公司经常性收入从 23 年的 570 万美元增加至了 1690 万美元。截至去年年底,和铂医药现金及现金等价物有 1.67 亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423225823a4640f38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423225823a4640f38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2529624123","title":"和铂医药-B盘中异动 早盘股价大涨5.01%报7.540港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529624123","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529624123?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:35","pubTimestamp":1745285728,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘09时35分,和铂医药-B股票出现波动,股价快速上涨5.01%。截至发稿,该股报7.540港元/股,成交量54.3万股,换手率0.07%,振幅5.57%。资金方面,该股资金流入235.072万港元,流出148.436万港元。和铂医药-B股票所在的生物技术行业中,整体涨幅为0.69%。其相关个股中,歌礼制药-B、来凯医药-B、荣昌生物涨幅较大,振幅较大的相关个股有博安生物、科伦博泰生物-B、歌礼制药-B,振幅分别为10.76%、10.72%、10.53%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422093528a461c162&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422093528a461c162&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02142","BK1574","BK1583"],"gpt_icon":0},{"id":"2528871908","title":"和铂医药-B(02142)4月17日斥资209.13万港元回购28.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2528871908","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528871908?lang=zh_cn&edition=full","pubTime":"2025-04-17 20:20","pubTimestamp":1744892451,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和铂医药-B(02142)发布公告,于2025年4月17日斥资209.13万港元回购28.9万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02142","BK1574","BK1583"],"gpt_icon":0},{"id":"2528796307","title":"和铂医药-B04月17日主力净流出519万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2528796307","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528796307?lang=zh_cn&edition=full","pubTime":"2025-04-17 16:16","pubTimestamp":1744877781,"startTime":"0","endTime":"0","summary":"04月17日,和铂医药-B股价收平报7.18元,成交金额3242万元,换手率0.53%,振幅4.74%,量比0.52。和铂医药-B今日主力资金净流出519万元,上一交易日主力净流入417万元。该股近5个交易日上涨12.06%,主力资金累计净流入260万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出2956万元,其中净流出天数为12日。该股主力净额占比0.09%,港股市场排名2616/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417170452a45c43c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417170452a45c43c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02142","BK1161","BK1574"],"gpt_icon":0},{"id":"2527214134","title":"和铂医药-B(02142)4月16日斥资539万港元回购75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527214134","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527214134?lang=zh_cn&edition=full","pubTime":"2025-04-16 20:46","pubTimestamp":1744807563,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和铂医药-B(02142)发布公告,于2025年4月16日斥资539万港元回购股份75万股,每股回购价格为6.97-7.35港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2527925968","title":"和铂医药人事变动:陈侑晨任首席财务官 直接向创始人汇报","url":"https://stock-news.laohu8.com/highlight/detail?id=2527925968","media":"GPLP犀牛财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527925968?lang=zh_cn&edition=full","pubTime":"2025-04-16 15:45","pubTimestamp":1744789536,"startTime":"0","endTime":"0","summary":"4月10日,和铂医药正式宣布任命陈侑晨为首席财务官。陈侑晨将常驻上海和中国香港两地,直接向公司创始人、董事长兼首席执行官王劲松博士汇报。自2023年加入和铂医药以来,陈侑晨深度参与投资者关系、全球合作伙伴关系建立及关键战略交易推进。然而,创新药研发周期长、资金需求大,对财务管理提出更高要求,陈侑晨能否拓宽融资渠道、优化资源配置仍待验证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041615462594d721dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041615462594d721dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2527850072","title":"和铂医药-B盘中异动 急速下跌5.48%报7.240港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527850072","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527850072?lang=zh_cn&edition=full","pubTime":"2025-04-16 10:47","pubTimestamp":1744771667,"startTime":"0","endTime":"0","summary":"2025年04月16日早盘10时47分,和铂医药-B股票出现波动,股价大幅下跌5.48%。截至发稿,该股报7.240港元/股,成交量190.5万股,换手率0.23%,振幅6.01%。资金方面,该股资金流入403.754万港元,流出860.673万港元。和铂医药-B股票所在的生物技术行业中,整体跌幅为3.06%。其相关个股中,荃信生物-B、复宏汉霖、中国抗体-B涨幅较大,振幅较大的相关个股有北海康成-B、歌礼制药-B、科伦博泰生物-B,振幅分别为15.56%、9.60%、7.99%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416104747aa2c70bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416104747aa2c70bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2527949291","title":"港股异动 | 医药股涨幅居前 再鼎医药(09688)涨近15% 和铂医药-B(02142)涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527949291","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527949291?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:57","pubTimestamp":1744595830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,医药股早盘涨幅居前,截至发稿,再鼎医药涨14.86%,报25.5港元;和铂医药-B涨10.07%,报7.87港元;荣昌生物涨8.22%,报30.95港元;君实生物涨8.1%,报15.22港元;来凯医药-B涨7.71%,报11.46港元。此外,财报层面:头部港股创新药公司受益于License-out放量,营收和利润稳步增长。该行表示,年初以来在DeepSeek的激励下,港股市场交投情形改善显著,相比之下,港股医药板块的关注度并不算高,对医药的基本面修复,市场定价或尚不充分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1277939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK1588","BK4585","BK4139","BK1583","LU1969619763.USD","BK4548","09688","BK1161","02105","LU2328871848.SGD","BK1574","02142","09939","159938","LU2488822045.USD","BK4526","01877","BK4588","ZLAB","BK1515","09995"],"gpt_icon":0},{"id":"1193399009","title":"港股生物医药股大幅上涨,永泰生物-B涨超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193399009","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193399009?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:40","pubTimestamp":1744594831,"startTime":"0","endTime":"0","summary":"4月14日,港股生物医药股大幅上涨,$永泰生物-B(06978)$涨超15%,$再鼎医药(09688)$涨超13%,$荣昌生物(09995)$、$和铂医药-B(02142)$、$腾盛博药-B(02137)$涨超6%.","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HSTECH","02137","BK4588","09688","BK1574","07226","LU2328871848.SGD","BK4531","02142","BK4139","BK1583","BK4585","BK4614","ZLAB","06978","HSCEI","YANG","09995","LU2488822045.USD"],"gpt_icon":0},{"id":"2518852758","title":"和铂医药-B早盘涨近8% 2024年12月初至今累计涨幅已超580%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518852758","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518852758?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:31","pubTimestamp":1741660260,"startTime":"0","endTime":"0","summary":" 和铂医药-B早盘继续上涨,2024年12月初至今累计涨幅已超580%。截至发稿,股价上涨7.90%,现报8.06港元,成交额6292.57万港元。 消息面上,和铂医药宣布正式任命Michael D. Patten担任首席战略官。在担任首席战略官期间,Michael将负责制定并统筹和铂医药全球业务发展战略及开发策略,深度管理、运营并强化公司的全球战略合作伙伴网络及生态圈,聚焦中国以外的高潜力海外市场,并进一步提升和铂医药的全球影响力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-11/doc-inepfzsp8816975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2518732389","title":"港股异动 | 和铂医药-B(02142)再涨超7% 公司正式任命首席战略官 负责拓展全球业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2518732389","media":"智通财经","labels":["executive","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518732389?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:05","pubTimestamp":1741658714,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,和铂医药-B再涨超7%,24年12月初至今累计涨幅已超580%。消息面上,和铂医药宣布正式任命Michael D. Patten担任首席战略官。值得注意的是,和铂医药此前宣布,根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议,公司已收到相应首付款,包括现金付款及Windward Bio母公司股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02142","BK1583","BK1574"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0731},{"period":"1month","weight":0.0126},{"period":"3month","weight":1.4071},{"period":"6month","weight":6.3417},{"period":"1year","weight":5.8295},{"period":"ytd","weight":3.7366}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0301},{"period":"3month","weight":0.1127},{"period":"6month","weight":0.0974},{"period":"1year","weight":0.236},{"period":"ytd","weight":0.1219}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。其中,巴托利单抗(HBM9161)主要用于免疫性血小板减少症、甲状腺相关性眼病、重症肌无力、视神经脊髓炎谱系疾病等. 特那西普(HBM9036)主要用于干眼病。此外,该公司还研究和开发肿瘤免疫产品管线,包括内部开发的新一代肿瘤免疫资产,针对治疗免疫沙漠型、免疫排斥型及炎症型肿瘤。该公司拥有Harbour Mice平台,该平台能够产生经典的双重链双轻链(H2L2)形式及仅重链(HCAb)形式的全人源单克隆抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.104328},{"month":2,"riseRate":0.2,"avgChangeRate":-0.004171},{"month":3,"riseRate":0.4,"avgChangeRate":0.046232},{"month":4,"riseRate":0.4,"avgChangeRate":0.013317},{"month":5,"riseRate":0.6,"avgChangeRate":0.037664},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069984},{"month":7,"riseRate":0.25,"avgChangeRate":0.010824},{"month":8,"riseRate":0,"avgChangeRate":-0.134459},{"month":9,"riseRate":0.25,"avgChangeRate":-0.098643},{"month":10,"riseRate":0,"avgChangeRate":-0.190485},{"month":11,"riseRate":0.75,"avgChangeRate":0.322177},{"month":12,"riseRate":0.75,"avgChangeRate":0.358142}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}